Phase II, Randomized, Investigator Initiated Trial to Evaluate Safety and to Explore Clinical Benefit of Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)
Latest Information Update: 09 Nov 2023
Price :
$35 *
At a glance
- Drugs Silmitasertib (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms CX4945
- 21 Jul 2023 Status changed from completed to discontinued.
- 04 Nov 2022 Status changed from active, no longer recruiting to completed.
- 31 May 2022 Status changed from recruiting to active, no longer recruiting.